Larsucosterol Phase 2b AHFIRM trial results published in NEJM Evidence in January 2025 Additional AHFIRM data presented in November 2024 at The Liver Meeting 2024 that informed the design of planned Phase 3 trial in alcohol-associated hepatitis (AH) Webcast of earnings call today, March 26 at 4:30 p.m. ET CUPERTINO, Calif. , March 26, 2025 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results... Read More

CUPERTINO, Calif. , March 19, 2025 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury, today announced that the company will report its fourth quarter and full year 2024 financial results on... Read More

CUPERTINO, Calif. , Feb. 4, 2025 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that James E. Brown, President and Chief Executive Officer, will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, to be held virtually, February 11-12, 2025. Presentation details are as follows: Date and time: Tue, Feb 11 at 2:00-2:30 PM ET (Track 5) Webcast:... Read More

The article presents new trial data, including subgroup analyses and liver biomarkers, which have guided the design of the Company's planned Phase 3 trial CUPERTINO, Calif. , Jan. 28, 2025 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the publication of a peer-reviewed article on the AHFIRM trial data in NEJM Evidence . The full article, entitled, "Larsucosterol for the Treatment of Alcohol-Associated... Read More

CUPERTINO, Calif. , Nov. 25, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury, today announced the sale of its ALZET ® line of osmotic pumps to Lafayette Instrument Co. (LIC), a portfolio company of Branford Castle Partners II, L.P.,... Read More

Seeking to initiate Phase 3 registrational trial for larsucosterol with topline results expected within two years of initiation Webcast of Earnings Call Today, November 13 at 4:30 p.m. ET CUPERTINO, Calif. , Nov. 13, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2024 and provided a business update. "We remain focused on preparations for the... Read More

CUPERTINO, Calif. , Nov. 6, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury, today announced that the company will report its third quarter financial results on Wednesday, November 13, 2024 . Management will also host a conference... Read More

CUPERTINO, Calif. , Oct. 17, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury, today announce that it will deliver an oral and two poster presentations at The Liver Meeting 2024 , organized by the American Association for the Study of... Read More

Type B meeting with FDA held under Breakthrough Therapy designation resulted in agreement on key aspects of Phase 3 trial design Single Phase 3 trial designed to enroll 200 U.S. patients with a 90-day survival primary endpoint; topline results expected within two years of trial initiation Protocol for Phase 3 trial builds on data from the AHFIRM Phase 2b trial; 30 mg and 90 mg doses of larsucosterol reduced 90-day mortality... Read More

CUPERTINO, Calif. , Sept. 4, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury and cancer, today announced management's participation in the H.C. Wainwright 26 th Annual Global Investment Conference to take place September 9-11, 2024... Read More

FDA Granted Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis Held Type B Meeting with FDA to Discuss Phase 3 Clinical Trial Design Seeking to Initiate Phase 3 Trial in 2024 with Topline Results Expected in 2H 2026 Webcast of Earnings Call Today, August 13th at 4:30 p.m. ET CUPERTINO, Calif. , Aug. 13, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results... Read More

CUPERTINO, Calif. , Aug. 7, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that the company will report its second quarter financial results on Tuesday, August 13, 2024 . Management will also host a... Read More

DURECT plans to confirm the efficacy and safety of larsucosterol in a registrational Phase 3 clinical trial CUPERTINO, Calif. , May 21, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury and cancer, today announced that the U.S. Food... Read More

FDA Feedback Supports Single Pivotal Trial for Approval of Larsucosterol in Alcohol-Associated Hepatitis Webcast of Earnings Call Today, May 13th at 4:30 p.m. ET CUPERTINO, Calif. , May 13, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2024 and provided a business update. "We are pleased that the feedback from the U.S. Food and Drug... Read More

CUPERTINO, Calif. , May 7, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that the company will report its first quarter financial results on Monday, May 13, 2024 . Management will also host a... Read More

CUPERTINO, Calif. , April 30, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury and cancer, today announced acceptance of a late-breaking oral presentation at the European Association for the Study of the Liver (EASL) Congress 2024 to... Read More

Ongoing Communication with FDA to Align on Next Steps for Larsucosterol in Alcohol-Associated Hepatitis Webcast of Earnings Call Today, March 27th at 4:30 p.m. ET CUPERTINO, Calif. , March 27, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the fourth quarter and year ended December 31, 2023 and provided a business update. "We remain enthusiastic about the improvement in 90-day... Read More

CUPERTINO, Calif. , March 20, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that the company will report its fourth quarter and full year 2023 financial results on Wednesday, March 27, 2024.... Read More

Partnership agreement will be the first-ever co-marketing and sales collaboration for the ALZET Osmotic Pumps Portfolio and Associated Product Line in the U.S. and Canada Both companies will jointly market and commercialize the ALZET product line to customers over a multi-year period CUPERTINO, Calif. , March 4, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), today announced that it has entered into a co-marketing... Read More

CUPERTINO, Calif. , Feb. 7, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that James E. Brown , President and Chief Executive Officer, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, to be held virtually, February 13-14, 2024 . Presentation details are as follows: Date and Time: Wednesday, February 14, 10:40 a.m. ET Webcast:... Read More

Webcast of Earnings Call Today, November 13th at 4:30 p.m. ET Topline data from AHFIRM trial showed compelling efficacy signal in favor of larsucosterol in the key secondary endpoint of mortality at 90 days CUPERTINO, Calif. , Nov. 13, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2023 and provided a corporate update. "The recently reported... Read More

CUPERTINO, Calif. , Nov. 9, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that the company will report its financial results for the three months ended September 30, 2023 on Monday, November 13, 2023... Read More

Compelling efficacy signal in favor of larsucosterol in the key secondary endpoint of mortality at 90 days. Clinically relevant reduction in 90-day mortality of 41% for 30 mg dose and 35% for 90 mg dose compared with standard of care (SOC) Numerical improvement in primary endpoint of mortality or transplant at 90 days did not achieve statistical significance More pronounced effect in the U.S. trial population of 232... Read More

Company on track to report topline data from AHFIRM in Q4 2023 CUPERTINO, Calif. , Sept. 7, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that the last patient has completed the study protocol in the... Read More

CUPERTINO, Calif. , Aug. 31, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program , will present in the following September 2023 conferences. H.C. Wainwright 25 th Annual Global Investment... Read More

Webcast of Earnings Call Today, August 9th at 4:30 p.m. ET Topline data from AHFIRM trial expected in Q4 2023 CUPERTINO, Calif. , Aug. 9, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2023 and provided a corporate update. "We are pleased to have completed enrollment in our Phase 2b AHFIRM trial in June and remain on track to report topline data in... Read More

CUPERTINO, Calif. , Aug. 3, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program, today announced that the company will report its financial results for the three months ended June 30, 2023 on... Read More

CUPERTINO, Calif. , July 20, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) ("DURECT"), a biopharmaceutical company focused on developing its epigenetic regulator program for the treatment of acute organ injury and chronic liver diseases, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 2,991,027 shares of common stock and accompanying warrants to purchase up... Read More

Topline data anticipated in Q4 2023 CUPERTINO, Calif. , June 7, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company developing epigenetic therapies for the treatment of acute organ injuries and chronic liver diseases, today announced that it has completed enrollment in its Phase 2b AHFIRM clinical trial ( NCT04563026 ) investigating larsucosterol for the treatment of patients with severe... Read More

Webcast of Earnings Call Today, May 8th at 4:30 p.m. ET Topline data from AHFIRM trial expected in 2H 2023 CUPERTINO, Calif. , May 8, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2023 and provided a corporate update. "We are rapidly approaching the completion of enrollment in our Phase 2b AHFIRM trial later this quarter and remain on track to... Read More

CUPERTINO, Calif. , May 1, 2023 /PRNewswire/ --- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its first quarter 2023 financial results and host a conference call after the market close on Monday, May 8, 2023 . Monday, May 8 @ 4:30pm Eastern Time / 1:30pm Pacific Time Toll Free: 1-877-869-3847 International: 201-689-8261 Conference ID: 13738577 Webcast:... Read More

CUPERTINO, Calif. , April 27, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it will host a Key Opinion Leader ("KOL") event on Alcohol-Associated Hepatitis on May 16th in New York City . Topics of discussion will include the etiology and prevalence of alcohol-associated hepatitis (AH), current treatment insufficiencies and unmet need for patients with AH, biology of larsucosterol, trial design and... Read More

CUPERTINO, Calif. , April 25, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James Brown , President and CEO, will participate in a fireside chat hosted by Ed Arce , Managing Director, Senior Biotechnology Research Analyst, H.C Wainwright & Co., LLC at the H.C. Wainwright BioConnect Investor Conference on May 2, 2023 . Details are as follows: H.C. Wainwright BioConnect Investor Conference... Read More

Data expands upon previously reported results, including individual patient data, additional liver biomarkers, and comparisons to matching arms from a contemporaneous study Company on track to report data from ongoing Phase 2b AHFIRM trial in 2H 2023 CUPERTINO, Calif. , April 10, 2023 /PRNewswire/ -- DURECT Corporation... Read More

CUPERTINO, Calif. , March 21, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Gail Maderis has assumed the role of Chair of the Board of DURECT effective March 17 , 2023. Ms. Maderis succeeds David Hoffmann as Chair of the Board. Mr. Hoffman has decided not to stand for re-election and will retire from the board on June 21, 2023 when his current term as a board member expires. "We thank Dave for... Read More

CUPERTINO, Calif. , March 9, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James Brown , President and CEO and additional members of the management team will participate in a fireside chat hosted by Francois Brisebois , Managing Director, Senior Biotechnology Research Analyst at Oppenheimer & Co. Inc. at the Oppenheimer 33 rd Annual Healthcare Conference on Wednesday, March 15 th , 2023.... Read More

Webcast of Earnings Call Today, March 7 th at 4:30 p.m. ET Topline data from AHFIRM trial expected in 2023 CUPERTINO, Calif. , March 7, 2023 /PRNewswire / -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months and year ended December 31, 2022 and provided a corporate update. "We are poised to complete enrollment in our potentially pivotal AHFIRM trial in the second quarter of 2023 and... Read More

CUPERTINO, Calif. , Feb. 28, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its fourth quarter and full year 2022 financial results and host a conference call after the market close on Tuesday, March 7, 2023 . Tuesday, March 7 @ 4:30pm Eastern Time / 1:30pm Pacific Time Toll Free: 1-877-869-3847 International: 201-689-8261 Conference ID: 13736560 Webcast:... Read More

CUPERTINO, Calif. , Feb. 3, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) ("DURECT"), a biopharmaceutical company focused on developing its epigenetic regulator program for the treatment of acute organ injury and chronic liver diseases, today announced that it has entered into a definitive agreement with a leading institutional healthcare investor and an existing institutional investor for the purchase and sale of... Read More

CUPERTINO, Calif. , Nov. 28, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on developing epigenetic regulator programs for the treatment of acute organ injury and chronic liver diseases, announced that DURECT's board of directors today determined that the Company will effect a reverse stock split at a ratio of 1-for-10 as of 5:01 p.m. Eastern Time on December 5, 2022 . Beginning... Read More